- 移动端
深圳欣博盛生物科技有限公司品牌商
16 年
手机商铺
商家活跃：
产品热度：
- NaN
- 0
- 0
- 2
- 2
全部产品
- 查看全部分类
- 欣博盛ELISA 试剂盒
- Vectorlabs
- GeneTex
- Peprotech
- Invivogen
- BioXcell
- FuGENE
- Prozyme
- Cayman
- Mirusbio
- ENZO(Alexis, Biomol, Assaydesign&stressgen)
- AbD Serotec
- Surmodics
- Millipore
- Metasystems
- Mabtech
- Proimmune
- Adipogen
- Bioporto
- Southern Biotech (SBA)
- Everest Biotech
- Chondrex
- IQ Products
- Atlas
- Detroit R&D
- StressMarq
- Cell Biolabs
- StrigoLab
- Synaptic Systems
- BioInnovatise
- Cosmo Bio
- Abwiz Bio
- Gerbu
- 蛋白
- 试剂类
- 抗体
- 分子化合物
- Cargille
- Antagen
- Nanoprobes
- Funakoshi
- Demeditec
- Enzo
- Fitzgerald
- Biovendor
- ICL
- Matreya
- PhaRNA
- Funakoshi
- Promise Advanced Proteomics
- Bioassay works
- NSJ Bio
- Aldevron
- CalBioreagents
- 3Helix
- 自产试剂盒
- TriLink
- Virostat
- Agilent
- Epicypher
- Jackson ImmunoResearch
推荐产品
公司新闻/正文
BioXcell新品推荐——InVivoMAb anti-mouse CD172a (SIRPα)单克隆抗体
658 人阅读发布时间：2019-06-12 16:10
研发背景：
P84单克隆抗体，也被称为CD172a抗体，可与信号调节蛋白α(SIRPα)反应。SIRPα蛋白是I型跨膜糖蛋白，在单核细胞、巨噬细胞和树突状细胞均有表达。此外，在神经元和中枢神经系统的一些其他组织也发现有SIRPα蛋白的表达。其配体CD47在多种细胞均有表达。
SIRPα和CD47参与调节由树突状细胞介导的T细胞的活化、中性粒细胞迁移和吞噬等过程。SIRPα蛋白可在巨噬细胞的细胞膜上进行横向扩散并在吞噬性突触中积累，与CD47结合后，抑制巨噬细胞的吞噬作用。
研究结果表明，使用anti-SIRPα抗体阻断SIRPα与CD47相互作用，可抑制小鼠体内肿瘤的形成。此外，P84（CD172a）单克隆抗体在体内和体外均具有中和活性。
BioXcell最新推出InVivoMAb anti-mouse CD172a (SIRPα)单克隆抗体，助力肿瘤免疫检查点研究。
产品信息：
Application References:
Yanagita, T., et al. (2017). "Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy." JCI Insight 2(1): e89140.
Koskinen, C., et al. (2013). "Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein alpha (SIRPalpha) signaling." J Biol Chem 288(41): 29333-29344.
Teraoka, Y., et al. (2013). "Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPalpha inhibitory signaling in mice." PLoS One 8(3): e58359.
Zen, K., et al. (2013). "Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state." Nat Commun 4: 2436.
Lundberg, P., et al. (2007). "Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction." Biochem Biophys Res Commun 352(2): 444-448.
Oldenborg, P. A., et al. (2001). "CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis." J Exp Med 193(7): 855-862.
详情请咨询 BioXcell 中国授权代理-欣博盛生物科技
全国服务热线: 4006-800-892 邮箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029 上海: 021-34613729
广州：18024516375 香港: 852-69410778
代理品牌网站: www.nbs-bio.com
自主品牌网站: www.neobioscience.net
糖型分析网站：www.glycan-analysis.com
P84单克隆抗体，也被称为CD172a抗体，可与信号调节蛋白α(SIRPα)反应。SIRPα蛋白是I型跨膜糖蛋白，在单核细胞、巨噬细胞和树突状细胞均有表达。此外，在神经元和中枢神经系统的一些其他组织也发现有SIRPα蛋白的表达。其配体CD47在多种细胞均有表达。
SIRPα和CD47参与调节由树突状细胞介导的T细胞的活化、中性粒细胞迁移和吞噬等过程。SIRPα蛋白可在巨噬细胞的细胞膜上进行横向扩散并在吞噬性突触中积累，与CD47结合后，抑制巨噬细胞的吞噬作用。
研究结果表明，使用anti-SIRPα抗体阻断SIRPα与CD47相互作用，可抑制小鼠体内肿瘤的形成。此外，P84（CD172a）单克隆抗体在体内和体外均具有中和活性。
BioXcell最新推出InVivoMAb anti-mouse CD172a (SIRPα)单克隆抗体，助力肿瘤免疫检查点研究。
产品信息：
| 产品货号 | BE0322 |
| 产品名称 | InVivoMAb anti-mouse CD172a (SIRPα) |
| 规格 | 1mg,5mg,25mg, 50mg, 100mg |
| 克隆号 | P84 |
| 同种型(Isotype) | Rat IgG1, κ |
| 免疫原(Immunogen) | Mouse brain membrane protein |
| 成分(Formulation) | PBS, pH 7.0 |
| Contains no stabilizers or preservatives | |
| 内毒素(Endotoxin) | <2EU/mg (<0.002EU/μg) |
| Determined by LAL gel clotting assay | |
| 纯度(Purity) | >95% |
| Determined by SDS-PAGE | |
| 无菌(Sterility) | 0.2 μM filtered |
| 生产(Production) | Purified from tissue culture supernatant in an animal free facility |
| 纯化(Purification) | Protein A |
| 保存(Storage) | Undiluted at 4°C in the dark |
| 应用(Reported Applications) | In vivo SIRPα blocking |
| In vitro SIRPα blocking | |
| Western blot |
Application References:
Yanagita, T., et al. (2017). "Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy." JCI Insight 2(1): e89140.
Koskinen, C., et al. (2013). "Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein alpha (SIRPalpha) signaling." J Biol Chem 288(41): 29333-29344.
Teraoka, Y., et al. (2013). "Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPalpha inhibitory signaling in mice." PLoS One 8(3): e58359.
Zen, K., et al. (2013). "Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state." Nat Commun 4: 2436.
Lundberg, P., et al. (2007). "Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction." Biochem Biophys Res Commun 352(2): 444-448.
Oldenborg, P. A., et al. (2001). "CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis." J Exp Med 193(7): 855-862.
详情请咨询 BioXcell 中国授权代理-欣博盛生物科技
全国服务热线: 4006-800-892 邮箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029 上海: 021-34613729
广州：18024516375 香港: 852-69410778
代理品牌网站: www.nbs-bio.com
自主品牌网站: www.neobioscience.net
糖型分析网站：www.glycan-analysis.com